|
Neoplasia
Citations 411-420 of 4217 total displayed.
|
Past content
(since Jan 1997):
|
Treatment-related risk factors for premature menopause following Hodgkin lymphoma
- Marie L. De Bruin, Jeannine Huisbrink, Michael Hauptmann, Marianne A. Kuenen, Gabey M. Ouwens, Mars B. van't Veer, Berthe M. P. Aleman, and Flora E. van Leeuwen
Blood 2008; 111: 101-108.
[Abstract]
[Full text]
[PDF]
Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)
- Holger Schulz, Ute Rehwald, Franck Morschhauser, Thomas Elter, Christoph Driessen, Thomas Rüdiger, Peter Borchmann, Roland Schnell, Volker Diehl, Andreas Engert, and Marcel Reiser
Blood 2008; 111: 109-111.
[Abstract]
[Full text]
[PDF]
Inhibition of tissue factor signaling suppresses tumor growth
- Henri H. Versteeg, Florence Schaffner, Marjolein Kerver, Helle H. Petersen, Jasimuddin Ahamed, Brunhilde Felding-Habermann, Yoshikazu Takada, Barbara M. Mueller, and Wolfram Ruf
Blood 2008; 111: 190-199.
[Abstract]
[Full text]
[PDF]
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies
- Katayoun Rezvani, Agnes S. M. Yong, Stephan Mielke, Bipin N. Savani, Laura Musse, Jeanine Superata, Behnam Jafarpour, Carol Boss, and A. John Barrett
Blood 2008; 111: 236-242.
[Abstract]
[Full text]
[PDF]
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
- Qing Liu, Xiaobin Zhao, Frank Frissora, Yihui Ma, Ramasamy Santhanam, David Jarjoura, Amy Lehman, Danilo Perrotti, Ching-Shih Chen, James T. Dalton, Natarajan Muthusamy, and John C. Byrd
Blood 2008; 111: 275-284.
[Abstract]
[Full text]
[PDF]
PKC  –mTOR pathway: a new target for rituximab therapy in follicular lymphoma
- Ludivine Leseux, Guy Laurent, Camille Laurent, Maxime Rigo, Amandine Blanc, Daniel Olive, and Christine Bezombes
Blood 2008; 111: 285-291.
[Abstract]
[Full text]
[PDF]
Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus–encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells
- Joanne R. Flavell, Karl R. N. Baumforth, Victoria H. J. Wood, Gillian L. Davies, Wenbin Wei, Gary M. Reynolds, Susan Morgan, Andrew Boyce, Gemma L. Kelly, Lawrence S. Young, and Paul G. Murray
Blood 2008; 111: 292-301.
[Abstract]
[Full text]
[PDF]
Accurate identification of paraprotein antigen targets by epitope reconstruction
- Seshi R. Sompuram, Gerassimos Bastas, Kodela Vani, and Steven A. Bogen
Blood 2008; 111: 302-308.
[Abstract]
[Full text]
[PDF]
Overexpression of CDX2 perturbs HOX gene expression in murine progenitors depending on its N-terminal domain and is closely correlated with deregulated HOX gene expression in human acute myeloid leukemia
- Vijay P. S. Rawat, Silvia Thoene, Vegi M. Naidu, Natalia Arseni, Bernhard Heilmeier, Klaus Metzeler, Konstantin Petropoulos, Aniruddha Deshpande, Leticia Quintanilla-Martinez, Stefan K. Bohlander, Karsten Spiekermann, Wolfgang Hiddemann, Michaela Feuring-Buske, and Christian Buske
Blood 2008; 111: 309-319.
[Abstract]
[Full text]
[PDF]
The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells
- Effi Wies, Yasuko Mori, Alexander Hahn, Elisabeth Kremmer, Michael Stürzl, Bernhard Fleckenstein, and Frank Neipel
Blood 2008; 111: 320-327.
[Abstract]
[Full text]
[PDF]
|
|
